Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for right ventricular dysfunction in adults with tetralogy of Fallot
NL-OMON41608Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of losartan in Cardiovascular Malformation (CVM), tetralogy of Fallot (TOF) and Right heart dysfunction (RHF), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in right ventricular ejection fraction. Started May 2014; status: active, not recruiting.
02
Drugs
losartan
03
Conditions
Cardiovascular Malformation (CVM)tetralogy of Fallot (TOF)Right heart dysfunction (RHF)
Beyond the preview
Go deeper on NL-OMON41608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41608.